Hepatocellular Carcinoma (HCC) Diagnostic
Hepatocellular carcinoma (HCC) is one of the most common tumors in the world and the third most frequent cause of cancer deaths. This type of cancer occurs more often in men than women. It is usually seen in people age 50 or older. However, the age varies in different parts of the world. The disease is more common in parts of Africa and Asia than in North or South America and Europe.
In most cases, the cause of liver cancer is usually scarring of the liver (cirrhosis). Some causes of cirrhosis include: alcohol abuse, autoimmune diseases of the liver, and Hepatitis B or C viral infection.
The prognosis is typicaly poor; only 10 - 20% of hepatocellular carcinomas can be removed completely using surgery. While survival rates vary, the disease is usually fatal within 3-6 months if the cancer is not completely removed.
Using our Human OneArray® microarray platform and a proprietary algorithm, Phalanx Biotech has identified a set of pathological biomarkers to predict the probability of HCC recurrence and metastasis in patients following surgery. This diagnostic signature is intended to provide physicians with an additional tool to devise proper post-surgery treatment and follow-up strategies for HCC patients.
In order to further validate this proprietary diagnostic signature, we are currently seeking US collaborators with access to a tissue repository of HCC samples. As a quality microarray manufacturer and service provider, we can provide our collaborators with a unique opportunity to participate in an innovative project that can benefit HCC patients globally. Please feel free to contact us for additional details.